Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.8.3577

Update of Research on Drug Resistance in Small Cell Lung Cancer Chemotherapy  

Chen, Yi-Tian (Department of Medical Oncology, Jinling Hospital)
Feng, Bing (Department of Medical Oncology, Jinling Hospital)
Chen, Long-Bang (Department of Medical Oncology, Jinling Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.8, 2012 , pp. 3577-3581 More about this Journal
Abstract
Small cell lung cancer (SCLC) is characterized by a short cell doubling time, rapid progression and early occurrence of blood-borne and lymph metastasis. The malignancy is the highest of all lung cancer types. Although SCLC has a relatively good initial response to chemotherapy as well as radiotherapy, relapse or disease progression may occur quickly after the initial treatment. Drug resistance, especially multi-drug resistance, is the most important cause of failure of SCLC chemotherapy. This article provides a brief update of research on mechanisms of drug resistance in SCLC and reversal strategies.
Keywords
Small cell lung cancer (SCLC); chemoresistance; targeted therapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Antonia SJ, Mirza N, Fricke I, et al (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res, 12, 878-87.   DOI
2 Coloff JL, Mason EF, Altman BJ, et al (2011). Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem, 286, 5921-33.   DOI
3 Demedts I, Vermaelen K, van Meerbeeck JP (2010). Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J, 35, 202-15.   DOI
4 Dy GK, Adjei AA (2002). Novel targets for lung cancer therapy: part I. J Clin Oncol, 20, 2881-94.   DOI
5 Fong KM, Sekido Y, Minna JD (1999) Molecular pathogenesis of lung cancer. J Thor Cardiovas Surg, 118, 1136-52.   DOI
6 Gemba K, Ueoka H, Kiura K, et al (2000). Immunohistochemical detection of mutant p53 protein in small cell lung cancer: relationship to treatment outcome. Lung Cancer, 29, 23-31,
7 GUAN Jun ming, YAN Yu sheng, BAI Yi feng, et al (2011). Investigation of multidrug resistant related genes of human SCLC using cDNA microarray. Guangdong Medical Journal, 32, 999-1001.
8 Guo L, Liu Y, Bai Y, et al (2010). Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer. Jun, 46, 1692-702.   DOI
9 Hann CL, Daniel VC, Sugar EA, et al (2008). Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2 in small cell lung cancer[J]. Cancer Res, 68, 2321-8.   DOI
10 Harley ME, Allan LA, Sanderson HS, et al (2010). Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J, 29, 2407-20.   DOI
11 Hodkinson PS, Mackinnon AC, Sethie T (2007 ). Extracellular matrix regulation of drug resistance in small-cell lung. Int. J Radiat Biol, 83, 733-41.   DOI
12 Inoue A, Ishimoto O, Fukumoto S, et al (2010). A phase II study of amrubicin combined with carboplatin for elderly patents with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Ann Oncol, 21, 800-3.   DOI
13 Jackman DM, Johnson BE (2005). Small-cell lung cancer. Lancet, 366, 1385-96.   DOI   ScienceOn
14 Jeong J, Cho BC, Sohn JH, et al (2010). Belotecan for relapsing small cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer, 70, 77-81.   DOI
15 Lawson MH, Cummings NM, Rassl DM, et al (2011). Two novel determinants of Etoposide resistance in small cell lung cancer. Cancer Res, 71, 4877-87.   DOI
16 Khanzada UK, Pardo OE, Meier C, et al (2006). Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene, 25, 877-87.   DOI
17 Knez L;Sodja E; Kern I, et al (2011). Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer, 72, 271-9.   DOI
18 Kohmo S, Kijima T, Otani Y, et al (2010). Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res, 70, 8025-35.   DOI   ScienceOn
19 Lee SM, James L, Buchler T, et al (2008) .Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer, 59, 364-8.   DOI
20 Mason EF, Zhao Y, Goraksha-Hicks P, et al (2010). Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res, 70, 8066-76.   DOI
21 Morimoto H, Tsukada J, Kominato Y, et al (2005). Reduced expression of human mismatch repair genes in adult T-cell leukemia[J]. Am J He-mato, 78, 100-7.   DOI
22 Oltersdorf T, Elmore SW, Shoemaker AR, et al (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-81.   DOI
23 Rigas JR, Denham CA, Rinaldi D, et al (2003). Adjuvant targeted therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI). Lung Cancer. 41, S34.
24 Sartorius UA and Krammer PH (2002). Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer, 97, 584-92.   DOI
25 Roberti A, La Sala D, Cinti C (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol, 207, 571-81.   DOI   ScienceOn
26 Rodriguez E, Lilenbaum RC (2010). Small cell lung cancer: past present and future. CurrD Oncol Rep, 12, 327 -34.   DOI
27 Rudin CM, Kozloff M, Hoffman PC, et al (2004). Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol, 22, 1110-7.   DOI
28 Song Y, Qi Y, Zhang W, et al (2005). Evolutionary trace analysis of eukaryotic DNA topoisomerase I superfamily: identification of novel antitumor drug binding site. Sci China C Life Sci, 48, 375-84.   DOI
29 Spigel DR, Hainsworth JD, Simons L, et al (2007). Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thor Oncol, 2, 854-61.   DOI
30 Tahir SK, Wass J, Joseph MK, et al (2010). Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/ lymphoma cell lines. Mol Cancer Ther, 9, 545-57.   DOI
31 Tang CH, Parham C, Shocron E, et al (2011). Picoplatin overcomes resistance to cell toxicity in small cell lung cancer precious treated with cisplatin and carboplatin. Cancer Chemother Pharmacol, 67, 1389-400.   DOI
32 Yeh JJ, Hsu NY, Hsu WH, et al (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung, 183, 177-83.   DOI   ScienceOn
33 Tan N, Malek M, Zha J, et al (2011). Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res, 17, 1394-404.   DOI
34 Weiss RH, Ramirez AL, Joo A (1999). Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and PI3 kinase. J Am Soc Nephrol, 10, 1880-90.
35 Wertz IE, Kusam S, Lam C, et al (2011). Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 471, 110-4.   DOI   ScienceOn